Inactive Instrument

Press Releases NeoStem Inc Nyse

Equities

NBS

US6406503051

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 23	Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer	MT
Apr. 23	Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	Apr. 24	AQ
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors	Apr. 23	AQ
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	Apr. 23	GL
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	Apr. 09	GL
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events	Apr. 03	GL
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma	Mar. 21	GL
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ	Mar. 04	AQ
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	Feb. 29	GL
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	Feb. 22	GL
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	Feb. 22	AQ
Lisata Therapeutics to Present at BIO CEO & Investor Conference	Feb. 20	GL
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico	Jan. 18	AQ
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme	Jan. 17	GL
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy	Jan. 04	GL
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy	Jan. 04	AQ
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma	Dec. 12	GL
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma	Dec. 12	AQ
Lisata Therapeutics to Present at NobleCon19 Investor Conference	Nov. 28	GL
Lisata Therapeutics Announces Participation in Upcoming Conferences in November	Nov. 09	GL
Lisata Therapeutics Announces Participation in Upcoming Conferences in November	Nov. 09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases NeoStem Inc Nyse

Equities

NBS

US6406503051

Press Releases

Filters